Overview

Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration (260 weeks: 5 years) of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment after healed erosive esophagitis (EE), and the curative effect of vonoprazan 20 mg versus lansoprazole in patients with EE.
Phase:
Phase 4
Details
Lead Sponsor:
Takeda
Treatments:
Dexlansoprazole
Lansoprazole